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Abstract Primary or premature ovarian insufficiency (POI)
is the most common long-term complication experienced
by girls and women with classic galactosemia; more than
80% and perhaps more than 90% are affected despite
neonatal diagnosis and careful lifelong dietary restriction of
galactose. In this review we explore the complexities of
timing and detection of galactosemia-associated POI and
discuss potential underlying mechanisms. Finally, we offer
recommendations for follow-up care with current options
for intervention.
Introduction
Galactosemia is an inborn error of metabolism that
results from impaired activity of any of the three
enzymes of the Leloir pathway: galactokinase (GALK,
EC 2.7.1.6), galactose-1-phosphate uridylyltransferase
(GALT, EC 2.7.7.12), or UDP-galactose 4′-epimerase
(GALE, EC 5.1.3.2) (reviewed in Fridovich-Keil and
Walter 2008). Classic galactosemia (OMIM 230400), the
most common clinically severe form of the disorder,
results from profound impairment of GALT. Classic
galactosemia impacts about 1/60,000 live births, although
prevalence differs substantially among populations
(reviewed in Fridovich-Keil and Walter 2008). Affected
newborns appear normal, but following exposure to milk,
which contains abundant galactose, develop symptoms
that can escalate rapidly from vomiting and diarrhea to
jaundice, failure to thrive, hepatomegaly, and E. coli
sepsis, which can be lethal. Neonatal diagnosis with
immediate dietary galactose restriction prevents or
resolves the acute symptoms of classic galactosemia.
However, despite even presymptomatic diagnosis and
strict lifelong dietary intervention, a majority of patients
go on to experience a constellation of troubling long-term
complications. Sequelae include cognitive and/or behav-
ioral impairment in close to half of all patients, speech
difficulties in at least half of all patients, low bone mineral
density in many patients, ataxia or tremor in some patients,
and primary or premature ovarian insufficiency (POI) in at
least 80% of all girls and women (reviewed in Fridovich-
Keil and Walter 2008).
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What is primary or premature ovarian insufficiency
(POI)?
Primary or premature ovarian insufficiency is a spectrum
disorder of ovarian dysfunction that differs considerably
among women. In its mildest form, POI may present as
diminished ovarian reserve with subfertility and often an
elevated FSH level in a woman’s fourth decade of life.
However, more severe forms of POI will present with
primary amenorrhea in the young adolescent with absent
sex steroid production and a complete lack of secondary
sexual characteristics. Many women with POI have an
intermediate phenotype, with normal progression through
puberty and later onset of irregular to absent menstrual
cycles and/or infertility. Proposed clinical criteria for the
diagnosis of intermediate POI include secondary amenor-
rhea for at least 4 consecutive months or more, prior to the
age of 40, in the setting of low estradiol and elevated FSH
(Goswami and Conway 2005; Welt 2008).
The term “primary ovarian insufficiency” was first used
in the literature more than 60 years ago (Albright 1942) and
was re-introduced recently as a more appropriate term to
replace less encompassing, compassionate, and descriptive
terms such as “premature ovarian failure” or “premature
menopause” that had come into use (Welt 2008). POI is not,
in fact, the early onset of natural menopause. Many women
with POI experience irregular ovarian function after their
diagnosis, with months of regular menses and ovulation
alternating with intervals of amenorrhea and hypoestrogen-
ism. Antral follicle counts, determined by ultrasound, and
serum FSH levels may vary considerably. This fluctuating
course of ovarian function is seldom seen once a woman
has experienced natural menopause and amenorrhea at a
more typical age. Of note, 5–10% of women given a
diagnosis of POI may still spontaneously conceive, and
there is very little evidence that any current treatment
increases this rate (Van Kasteren and Schoemaker 1999).
The prevalence of POI in the general population is not
entirely known. An often quoted incidence of 1% is based
largely on a 1986 study of female residents of Rochester, MN
(Coulam et al. 1986). Of women in this cohort between the
ages of 15 and 29, the incidence of POI was 1 in 10,000; for
women between the ages of 30 and 39, it was 7.6 in 10,000.
In contrast, the majority of reported information about the
prevalence of diminished ovarian reserve comes from data
on infertility patients. In 2007, 13% of women who
underwent in vitro fertilization for infertility were diagnosed
with diminished ovarian reserve (Centers for Disease Control
and Prevention 2007). However, the prevalence of dimin-
ished ovarian reserve in the general population is unclear, in
part because many cases may remain subclinical.
While there are many recognized causes of POI, in the
majority of cases the etiology remains unknown. Approxi-
mately 23% of cases are caused by Turner’s syndrome or
mosaicism for monosomy X (Conway 2000); this is the
single most frequently recognized genetic cause of POI.
Approximately 20% of women with POI show evidence of
autoimmune disease (LaBarbera et al. 1988). Ovarian
insufficiency has been associated with autoimmunity in a
variety of organs including autoimmune Addison’s disease,
Hashimoto’s thyroiditis, type 1 diabetes, rheumatoid arthritis,
pernicious anemia, celiac sprue, vitiligo, lupus, Sjörgren’s
syndrome, and autoimmune polyendocrine syndromes I and
II (Wheatcroft and Weetman 1997). Abnormal karyotypes
other than monosomy X represent a small contribution
(Persani et al. 2009), and many single gene defects, other
than galactosemia, have also been identified in families with
POI; the most significant of these is the fragile X
premutation, which accounts for roughly 5% of women with
POI (Bussani et al. 2004; Conway et al. 1998; Gersak et al.
2003; Murray et al. 1998). Other notable mutations
associated with POI involve the genes folliculogenesis
growth factor GDF-9, BMP-15, and the sex determining
factor FOXL2. (Crisponi et al. 2001; Di Pasquale et al. 2004;
Laissue et al. 2006). Mutations impairing the expression or
function of FSH (B subunit) or FSH receptor may also
contribute to apparent ovarian dysfunction, although the
former results in low levels of FSH, which would be atypical
for POI (reviewed in Rubio-Gozalbo et al. 2010).
POI in galactosemia
The most common long-term complication reported for
girls and women with profound GALT deficiency is POI,
with an incidence of >80% and perhaps >90% (e.g.,
Kaufman et al. 1981; Waggoner et al. 1990; reviewed in
Berry 2008; Fridovich-Keil and Walter 2008; Rubio-
Gozalbo et al. 2010). Of note, patients with trace levels of
residual GALT activity may demonstrate a milder pheno-
type (Berry 2008; Guerrero et al. 2000; Kaufman et al.
1988), leading to confusion or controversy in some
instances. There have been no reports of ovarian dysfunc-
tion among women with Duarte galactosemia (who dem-
onstrate about 25% normal GALT activity), and a cohort of
galactosemia carrier women demonstrated apparently nor-
mal ovarian reserve and age at menopause (Knauff et al.
2007), although many of the women in that study were
ascertained on the basis of their children, meaning there
may have been a bias in the cohort toward women who
were (or had been) fertile.
POI detection in prepubertal girls with classic galactosemia
Because of its prevalence in the patient population, there
has been considerable interest in presymptomatic diagnosis
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of POI among prepubertal girls with classic galactosemia.
Until recently, the only minimally invasive approach
involved measurement of blood FSH values and estradiol
values. However, FSH is an indirect measure, reflecting the
hypothalamic response to diminished ovarian function, and
this response may be absent in prepubertal girls. Ovarian
imaging studies in prepubertal girls might also be informa-
tive, but these are more complex and are not routinely
performed, especially on very young girls.
Recently we reported data suggesting that anti-Müllerian
hormone (AMH), which is produced by granulosa cells of
primary through late preantral and preovulatory follicles (La
Marca and Volpe 2006), may provide a meaningful predictor
of ovarian function in prepubertal girls with classic galacto-
semia (Sanders et al. 2009). In nongalactosemic women,
AMH levels correlate with antral follicle counts visible by
ultrasound and also with histologically determined primor-
dial follicle counts (Hansen et al. 2010). While the reported
results with galactosemic girls were promising, longitudinal
studies will be needed to test the true predictive value of
serum or plasma AMH levels measured in this population.
Timing of the onset of POI in galactosemia
POI in galactosemia may manifest as primary amenorrhea,
secondary amenorrhea, or oligomenorrhea. Explanations for
any of these outcomes could include a reduced initial
oocyte pool, increased follicular atresia during develop-
ment, or perhaps diminished maturation of primordial
follicles. Determining the point in development at which
POI begins has been difficult; whether the fundamental
defect arises prenatally, in infancy, or later in childhood,
ovarian insufficiency is not clinically apparent until
puberty. Furthermore, a GALT-deficient animal model has
not yet been reported that recapitulates the reproductive
phenotype. However, results from numerous studies sug-
gest that galactosemia-associated ovarian dysfunction has
its roots in early development.
Newborn screening for galactosemia and prenatal diagno-
sis have allowed for early initiation of dietary galactose
restriction; unfortunately, these advances have not led to a
reduced incidence of POI in galactosemia (Rubio-Gozalbo et
al. 2006; Schweitzer et al. 1993; Waggoner et al. 1990). The
failure of dietary galactose restriction to improve reproduc-
tive outcomes suggests that GALT deficiency may first affect
ovarian tissue in the pre- or perinatal period, prior to
diagnosis and intervention. Those animal studies that have
been reported support this hypothesis. In genetically wild-
type rats, prenatal exposure to a high level of galactose has
been shown to interfere with the migration of primordial
germ cells to the developing gonad (Bandyopadhyay et al.
2003), and female pups demonstrate reduced initial oocyte
pools (Chen et al. 1981).
Galactosemic females are undoubtedly exposed to
galactose prenatally: galactose, galactitol, and gal-1-P
levels have all been detected at abnormally high levels in
the tissues of galactosemic fetuses (Holton 1995). This
accumulation in utero is most likely due to self-intoxication
from de novo galactose synthesis. Leloir enzyme activity is
detectable in the human fetal liver by the 10th week of
gestation (Holton 1995), and maternal adherence to a
lactose-restricted diet does not prevent accumulation of
galactose metabolites in the cord blood (Irons et al. 1985)
or amniotic fluid (Jakobs et al. 1988) of galactosemic
newborns.
Studies of serum biomarkers used to assess ovarian
status in galactosemic girls also suggest that
galactosemia-associated POI begins in early life. Serum
AMH levels, used clinically as an indicator of follicular
function and ovarian reserve (La Marca and Volpe 2006),
are abnormally low in galactosemic girls relative to age-
matched controls, even in girls younger than 2 years
(Sanders et al. 2009). Elevated FSH level, an indirect
measure of ovarian function, has been observed in
galactosemic girls as early as 10 months of age and may
remain high throughout the prepubertal years (Beauvais
and Guilhaume 1984; Gitzelmann and Steinmann 1984;
Irons et al. 1986; Kaufman et al. 1986; Schwarz et al.
1986; Steinmann et al. 1981; reviewed in Berry 2008;
Rubio-Gozalbo et al. 2006, 2010). FSH production in
response to GnRH stimulation is also abnormally high in
classic galactosemics (reviewed in Berry 2008).
Combined, these findings suggest that the ovaries of
most galactosemic girls are already functionally different in
neonatal life with possible toxicity starting in fetal life. This
may lead to fewer follicles at birth resulting in accelerated
depletion of follicles in this population of girls and women.
However, FSH measurements in prepubertal girls may be
misleading. For example, prior to the age of 2 years an
elevated FSH level may reflect factors independent of
ovarian function of the child, and even a normal FSH level
in a prepubertal girl is not fully reassuring since the
hypothalamic-pituitary-ovarian (HPO) axis is thought to
be quiescent after 1–2 years of age and not fully reactivated
until just prior to puberty (Conte et al. 1975). Whether
timing of the HPO axis is altered in galactosemic girls
remains unclear. Thus, depending on whether the HPO axis
is active in a given prepubertal girl, her FSH levels may not
start to rise until early puberty even if her ovaries are
dysfunctional.
Morphologic and histologic studies of ovaries from
galactosemic girls might provide more insight into the
timing of onset of ovarian dysfunction, but the limited
studies that have been published are mostly confined to
women in whom POI had already been diagnosed. In
two case reports concerning prepubertal girls, the ovaries
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appeared normal; postmortem examination of a galacto-
semic newborn who died of E. coli sepsis revealed
morphologically normal ovaries containing abundant
oocytes (Levy et al. 1984), and a 7-year-old girl
undergoing ultrasound for appendicitis was also found to
have ovaries that appeared normal. Intriguingly, this same
girl was later diagnosed with POI and underwent
laparoscopy at age 17, which revealed streak ovaries
(Kaufman et al. 1981). In imaging studies of girls with
POI examined at pubertal age or later, the ovaries are
invariably abnormal and usually described as hypoplastic
or “streak-like.” Histological examination most often
shows few if any follicles; in the cases where follicles
have been observed they did not appear to have matured
beyond the primordial stage (reviewed in Rubio-Gozalbo
et al. 2010).
Lack of information on ovarian morphology and
histology in a majority of galactosemic girls in infancy
and early childhood makes it impossible to determine
whether the diminished ovarian tissue seen in older girls
and women reflects a failure of development, a regression
of ovarian tissue over time, or a combination of both. The
one documented case of apparently normal ovaries later
becoming streak-like (Kaufman et al. 1981) suggested that
the mechanism may be related to accumulated galactose
ootoxicity over time.
Animal studies of galactose exposure reinforce the
notion that the galactosemic ovary remains vulnerable to
damage throughout life. The ovaries of genetically wild-
type rats fed a high galactose diet exhibit decreased
follicular development (Liu et al. 2006) and increased
apoptosis of maturing follicles (Lai et al. 2003). In mice,
preferential activation of the prolactin short-form receptor
in the ovary, which represses FOXO3 and subsequently
inhibits GALT expression, results in accelerated follicular
depletion and consequent ovarian failure (Halperin et al.
2008). These studies indicate that even in the absence of
developmental damage to the ovary, later exposure to
galactose or its metabolites may contribute to POI, both
by suppressing normal follicular maturation and by increas-
ing follicular death.
Recent reports that, at least in some galactosemic
women, POI follows a fluctuating course (Gubbels et al.
2008, 2009) are also suggestive of multiple layers of
galactose ootoxicity. These observations are also consistent
with the apparently fluctuating course of POI in many
women who do not have galactosemia (Van Kasteren and
Schoemaker 1999). For these women, prohibition of
primordial follicle maturation may be intermittently re-
lieved by an as yet unknown mechanism, allowing for
intervals of spontaneous ovulation, normal menstrual
cycles, and fertility. Of note, one study of a small cohort
of galactosemic women looked at spontaneous fertility
outcomes (Gubbels et al. 2008) and reported that galacto-
semia patients with a diagnosis of POI may be more likely
to conceive than women who have POI due to other causes.
This possibility needs to be studied in a larger cohort
because it may alter how galactosemic patients are
counseled about their probability of conceiving.
Possible mechanisms underlying POI in galactosemia
The question remains: What makes the human ovary so
vulnerable to profound GALT deficiency? Though the
answer remains elusive, a number of logical scenarios
have been postulated (reviewed in Berry 2008); these
include increased apoptosis of oocytes and/or ovarian
stromal cells due to the individual or combined effects of
excess gal-1P, galactitol, and/or other galactose metabo-
lites, or defective glycosylation of ovarian or other
proteins or lipids leading to direct and/or indirect ovarian
dysfunction. Of course, the formal possibility also remains
that GALT may have "moonlighting" functions indepen-
dent of the Leloir pathway that are essential for ovarian
function. However, reports of a correlation between milder
ovarian dysfunction and the presence of residual GALT
activity (Kaufman et al. 1988; Waggoner et al. 1990) or
residual ability to metabolize galactose as measured by
whole body galactose oxidation (Guerrero et al. 2000)
argue against this possibility. Historically, women with
GALK deficiency have not been considered at increased
risk of POI, yet they accumulate galactose and/or
galactitol in their blood and tissues; the individual roles
of galactose and/or galactitol in ovarian toxicity must,
therefore, be viewed with some caution. That said,
profound GALK deficiency is extraordinarily rare, so that
all studies of patient outcome are, by definition, studies of
small cohorts (reviewed in Fridovich-Keil and Walter
2008). The long-term natural history of GALK-deficiency
may therefore be imperfectly understood, leaving open the
possibility that some subtle ovarian dysfunction impacts at
least a subset of these patients.
Direct ovarian damage?
Direct ovarian damage could occur via a number of
possible routes. Galactose may cause deposition of methy-
glyoxal by hampering the glutathione redox cycle and
enhancing apoptosis (Liu et al. 2000). Similarly, galactitol,
which is metabolized poorly, may accumulate in ovarian
cells causing osmotic stress, swelling, and cell dysfunction.
Glutathione levels may decrease, allowing increased hy-
drogen peroxide accumulation and apoptosis (Meyer et al.
1992). Finally, gal-1P may inhibit key enzymes that
normally metabolize glucose-1P, impairing cellular metab-
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olism (Gitzelmann 1995), and/or leading to increased cell
stress (Slepak et al. 2005).
Studies on the effects of excess galactose in rat
invariably show ovarian damage. Pregnant rats fed a
50% galactose diet showed a striking reduction in oocyte
number in female pups; the most prominent effects were
noted after exposure to galactose during the premeiotic
stages of oogenesis (Chen et al. 1981). Female mice fed a
50% galactose diet for 2, 4, or 6 weeks demonstrated a
decrease in the normal ovulatory response, as evidenced
by a reduction in the number of corpora lutea when
compared with controls (Swartz and Mattison 1988).
Further, exposure of galactose-treated mice to a super-
ovulatory regimen of pregnant mare’s serum gonadotropin
(PMSG) and human chorionic gonadotropin (hCG) also
failed to induce the anticipated increase in ovulatory
response (Swartz and Mattison 1988); this effect was
reversible upon cessation of galactose exposure (Swartz
and Mattison 1988). In another study, pregnant rats were
fed pellets with or without a 35% galactose supplement
from day 3 of conception through weaning of their pups
(Bandyopadhyay et al. 2003). Female pups were evaluated
for serum levels of galactose and galactose-1-phosphate,
growth rate, onset of puberty, reproductive cyclicity,
ovarian complement of follicles, hypothalamo-pituitary-
ovarian function, and follicular response to gonadotropins.
Galactose in the maternal diet delayed the onset of puberty
and also increased the frequency of hypergonadotropic
hypoestrogenism in the female pups (Bandyopadhyay et
al. 2003).
Indirect ovarian damage?
Another potential mechanism underlying POI in classic
galactosemia involves indirect damage resulting from
aberrant glycosylation. For example, appropriate levels
and ratios of UDP-galactose and UDP-glucose are needed
for proper synthesis of ovarian glycoproteins and glyco-
lipids and also for support of germ cells, follicle maturation,
and steroidogenesis. Numerous reports have demonstrated
that GALT deficiency leads to aberrant glycosylation,
especially prior to dietary galactose restriction (Charlwood
et al. 1998; Dobbie et al. 1990; Haberland et al. 1971;
Jaeken et al. 1992; Ornstein et al. 1992; Petry et al. 1991;
Prestoz et al. 1997; Stibler et al. 1997; Sturiale et al. 2005).
The structures of the truncated glycans detected in patient
samples are consistent with a decreased capacity to
galactosylate glycoproteins. In some cases the truncated
N-glycans observed persist, albeit in small proportion, even
after dietary treatment (Charlwood et al. 1998), however,
the clinical relevance of these glycosylation abnormalities
is not clear. For example, although Prestoz and colleagues
(1997) reported finding a subpopulation of ostensibly
abnormally glycosylated FSH in the blood of galactosemic
women relative to controls, two direct tests of FSH
bioactivity conducted more than 25 years apart using
different sample sets and different methods both demon-
strated no statistically significant difference between
patients and controls (Kaufman et al. 1981; Sanders et al.
2009).
Gonadotropins and their receptors undergo extensive
posttranslational modifications, including glycosylation,
that are crucial for their longevity and function in vivo
(Ulloa-Aguirre et al. 1995). For example, less acidic
isoforms of recombinant FSH that carry incomplete or
aberrant glycan additions have been found to have a shorter
half-life (de Leeuw et al. 1996). In the FSH receptor, N-
glycosylation occurs co-translationally and plays a role in
the maturation and processing of the receptor (Menon et al.
2005). Interestingly, patients with primary congenital
disorders of glycosylation type 1, due to mutations that
affect the glycosylation machinery itself, also may have
ovarian insufficiency based on hypergonadotropic hypogo-
nadism (Kristiansson et al. 1995). Similar to classic
galactosemics, these patients tend to have high concen-
trations of FSH in infancy, perhaps suggesting a similar
mechanism of pathophysiology (Kristiansson et al. 1995).
An epigenetic mechanism?
Another possible mechanism of POI in classic galactosemia
that needs to be explored involves prenatal or neonatal
disturbance of the expression of genes involved in follicle
development (Coman et al. 2010; Lai et al. 2008). Recently,
the human tumor suppressor gene aplysia ras homolog 1
(ARHI), which is involved in ovarian folliculogenesis, was
proposed as a possible target of toxicity in classic
galactosemia (Lai et al. 2008). This gene is missing in
rodents (Fitzgerald and Bateman 2004), and re-expression
of this gene in mice causes failure of ovarian follicular
maturation, poor growth, and impaired Purkinje cell
development (Xu et al. 2000). ARHI is expressed consis-
tently in normal ovarian cells (Yu et al. 1999).
Another gene that may be involved is NR5A1 (Lourenço
et al. 2009). As confirmed by studies in mice, NR5A1
encodes a transcriptional regulator of genes that mediate the
hypothalamic-pituitary-steroidogenic axis in both males and
females. Recent studies of 25 women with sporadic ovarian
insufficiency revealed that two carried mutations in NR5A1
that were not found in >700 control alleles, and functional
studies using a tissue culture system demonstrated that
these mutations impaired NR5A1 transactivational activity
(Lourenço et al. 2009). Whether the ovarian insufficiency
experienced by girls and women with classic galactosemia
results from impairment of a pathway that involves NR5A1
remains unclear.
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Recommendations for follow-up of girls and women
with classic galactosemia, and potential intervention
for POI in this population
Treatment of delayed or absent puberty
Currently, the treatment of galactosemic girls and women
with ovarian insufficiency focuses mainly on estrogen
supplementation to avoid secondary effects of hypoestro-
genism. Unless the patient does not have a uterus,
progesterone must be added at some point to reduce the
risk of endometrial hyperplasia or cancer. Some physicians
test for hypergonadotropism beginning after the age of
8 years, and then induce pubertal development at an age-
appropriate time by estrogen supplementation if FSH and
LH values are increased. However, high gonadotropin
values may be found in these girls even at a very early
age (Beauvais and Guilhaume 1984; Gitzelmann and
Steinmann 1984; Irons et al. 1986; Kaufman et al. 1986;
Schwarz et al. 1986; Steinmann et al. 1981; reviewed in
Berry 2008; Rubio-Gozalbo et al. 2006, 2010) perhaps
indicating early ovarian insufficiency resulting in a dis-
turbed hypothalamic-pituary-ovarian axis. Therefore, the
absence of developing secondary sex characteristics may be
a more important benchmark of when to initiate therapy.
Previously, most physicians waited until a patient was at
least 16 years of age to induce pubertal development with
exogenous hormones if it had not occurred spontaneously
(Gubbels et al. 2008); this practice led to a higher
percentage of spontaneous menarche in the older cohort.
However, postponing the induction of pubertal develop-
ment to age 16 can have psychological disadvantages if
classmates have pubertal development earlier. There may be
physiological detriments as well, although this point
remains unclear.
In the U.S., most clinicians currently initiate hormone
replacement therapy (HRT) in girls with ostensible ovarian
insufficiency between 12 and 14 years of age. Timing may
be influenced by bone age, parental request, and growth
velocity (Drobac et al. 2006). Initiating hormone replace-
ment too early in girls with Turner’s syndrome has been
shown to decrease maximum height (Chernausek et al.
2000), demonstrating the risk of premature intervention. In
Europe, a study of clinical practice demonstrated that
40.4% of clinicians initiate treatment by age 11, 47.8%
wait until age 13, and 7.5% wait until age 15 (Kiess et al.
2002). Since very low doses of estrogen may stimulate
growth velocity in an adolescent with delayed puberty and
higher doses may result in premature closure of the
epiphysis, initial replacement at a relatively low dose
should be considered with slow titration over several years
(Sas et al. 1999; van Teunenbroek et al. 1996) to enable
affected girls to reach higher adult stature.
There are many formulations and routes of administration
for HRT. The most commonly prescribed are oral conjugated
equine estrogens or oral 17β-estradiol (Drobac et al. 2006;
Kiess et al. 2002). Transdermal and transvaginal administra-
tion of 17β-estradiol is becoming more popular for
postmenopausal hormone therapy because it may be associ-
ated with less risk of venothromboembolism (Canonico et al.
2010). Further research is needed in young women with POI
to determine which route of administration is best.
Risks of HRT in women with POI
Specific information on risks of HRT in POI remains
scarce, as most studies have been performed in postmen-
opausal women, and these results should not be extrapolat-
ed to younger women (Armitage et al. 2003). One aspect
that deserves further investigation is whether HRT in young
women with ovarian insufficiency should continue until the
average age at menopause. Women with POI have a two-
fold increased risk of mortality, and while large randomized
trials are lacking, HRT may ameliorate endothelial dys-
function in young women (Kalantaridou et al. 1998, 2004)
and delay the onset of osteoporosis, a prevalent complica-
tion of POI (Anasti et al. 1998). In the absence of
contraindications, HRT remains the best treatment option
known for menopausal symptoms (hot flashes, vaginal
dryness, etc.) in women with hypoestrogenism from POI.
Fertility treatment options
A general treatment strategy for women experiencing
hypogonadotropic or normogonadotropic anovulation is
ovulation induction with the administration of urinary or
recombinant gonadotropins. However, for success this
treatment requires the presence of responsive follicles,
which may be a problem for women with classic galacto-
semia. If the ovarian dysfunction seen in galactosemia
results from a follicular maturation arrest (Liu et al. 2006;
Xu et al. 2000), then longer-term stimulation (for example,
for several months) might, in theory, be beneficial (Gubbels
et al., personal observation ). However, one might question
the likelihood of benefit of administering exogenous FSH
to a woman whose endogenous FSH is already elevated,
unless, of course, the endogenous FSH is functionally
impaired, which appears not to be the case (Kaufman et al.
1981; Sanders et al. 2009). Anecdotal evidence from a case
report (Menezo et al. 2004) suggests there may be some
role for exogenous gonadotropins; this possibility needs to
be explored in a larger, placebo-controlled trial.
For those women in whom ovarian stimulation fails or
cannot be performed, oocyte donation is an option.
Pregnancy after this procedure has been described in
galactosemia (Sauer et al. 1991). Egg donation is not
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readily available in all countries; some impose restrictions
on the use of anonymous and compensated donors (e.g.,
Schenker 1997; Uroz and Guerra 2009). Furthermore, the
treatment is costly and prior psychological counseling is
recommended. However, this treatment is effective; com-
pared to the chances of spontaneous pregnancy, the
probability of conception with egg donation is significantly
higher. In the U.S., egg donation IVF cycles have an
approximate 55% chance of live birth per cycle (Centers for
Disease Control and Prevention 2007).
Fertility preservation options
Options to preserve endogenous fertility in galactosemia
need to be explored further. For postpubertal women,
freezing embryos after in vitro fertilization is an option
that is currently available, with good results. The probabil-
ity of pregnancy resulting from frozen embryo transfers in
the U.S. is approximately 30% per transfer (Centers for
Disease Control and Prevention 2007). This success rate
requires that the egg be fertilized with either the partner’s
sperm or with donor sperm prior to cryopreservation,
however, so this technology may not be a preferred option
for every woman. Furthermore, this technique requires that
the woman seeking treatment produce a relatively large
number of oocytes with controlled ovarian hyperstimula-
tion. If galactosemia does cause a diminished oocyte pool
or impaired maturation of oocytes, as animal studies
suggest (Liu et al. 2006; Xu et al. 2000), response to
hormonal stimulation may be insufficient to justify the
procedure. Reports to date involving galactosemic women
are extremely limited.
In the prepubertal girl, ovarian tissue cryopreservation
has been named as a possible mode to preserve fertility, and
in Denmark, ovaries of galactosemic girls have already
been frozen (Danish Galactosemia Society, personal com-
munication). There are, however, several problems with this
strategy worth considering. The current state of ovarian
cryopreservation technology is not reliably established and
pregnancies resulting from these procedures are rare;
recommending this procedure may therefore offer false
hope to galactosemic patients and their families. Indeed,
both the American College of Obstetrics and Gynecology
(ACOG) and the American Society of Reproductive
Medicine (ASRM) currently recommend that women only
undergo oocyte or ovarian cryopreservation as part of a
research study as the technology is not yet ready for clinical
use (ACOG 2008). Improvements in this technique,
however, may be of great benefit. Trials are currently
ongoing for (nongalactosemic) women trying to preserve
fertility before needed chemotherapy and radiation treat-
ment that may yield valuable information and improved
options for galactosemic girls (Backhus et al. 2007; Grifo
and Noyes 2010; Noyes et al. 2010). Unfortunately, if
ovarian insufficiency has already occurred in early child-
hood, cryopreserving tissue after that point may be too late.
In addition, whether these invasive procedures should even
be considered for children is controversial.
Pregnancy in galactosemia
For those women with galactosemia who do achieve
pregnancy, evidence from studies of small cohorts suggest
that there are no adverse effects on the galactosemic mother
or her infant (Gubbels et al. 2008; Schadewaldt et al. 2009).
There is, however, a lack of long-tem prospective informa-
tion on this subject. It is clear that pregnancy does not lead
to metabolic crisis, but most patients have increased
metabolite values. A prospective follow-up study of
patients who try to conceive might provide useful informa-
tion that is currently only available in anecdotal form.
Long-term follow-up of children born to galactosemic
mothers would also be of interest. Current data from animal
models are mixed. Offspring of rats fed a high galactose
diet have a lower birth weight and placental weight
compared to controls, although catch-up growth is seen as
soon as the galactose intake is normalized (Spatz and Segal
1965). Rats born to mothers with high galactose intake also
have larger livers with less liver-enzyme activity, but these
abnormalities also resolve in the postnatal period after diet
normalization (Spatz and Segal 1965). Offspring of rats fed
a high galactose diet have smaller brains than rats born to
mothers fed a normal diet (Haworth et al. 1969), indicating
a possible effect on brain development. Cataracts in the
offspring of rats fed a high galactose diet during pregnancy
are also common (Segal and Bernstein 1963), but are
completely reversible as soon as galactose intake is
normalized. Of particular concern, a reduction in the
number of oocytes at birth is seen in female pups born to
rats fed a high galactose diet during pregnancy (Chen et al.
1981). Whether any of these observations from rodents
foretell concerns for humans remains unclear, but they
could and should be tested through long-term follow-up
studies.
Challenges, uncertainties, and opportunities
Supplemental approaches to intervention?
That POI and other long-term complications are so
common among treated patients with classic galactosemia
reinforces the unavoidable conclusion that current interven-
tion is inadequate. One approach to supplemental treatment
that has been raised in the galactosemia literature proposes
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use of a small molecule inhibitor to block GALK function
(Bosch 2006; Wierenga et al. 2008). The idea, in short, is to
block accumulation of gal-1P in patient cells by blocking
its synthesis, ostensibly converting the metabolic status and
outcome of a GALT-deficient patient into that of a GALK-
deficient patient.
This idea seems reasonable in theory, and some
candidate inhibitors have already been reported (Wierenga
et al. 2008); however, a number of challenges remain. First,
are GALK-deficient patients truly unaffected beyond the
well-described galactose-dependent cataracts? Second, how
much GALK inhibition would be required to prevent gal-
1P accumulation, and in what tissues? Studies in yeast
(Mumma et al. 2008) suggest that GALK inhibition would
need to be profound to impact gal-1P accumulation in a
significant way. Logical consideration suggests another
problem, namely that GALK inhibition is a cell-
autonomous effect; inhibiting GALK in one cell might
limit the accumulation of gal-1P in that cell, but it would do
nothing to lower the accumulated galactose in the blood, or
the accumulation of gal-1P in other cells. Drug delivery
would therefore need to be truly systemic, including across
the blood-brain barrier.
Other treatment options that deserve attention include
tissue or organ transplantation, for example liver, and in
vivo or ex vivo gene therapy. The possibility of restoring
GALT activity by introducing a normal population of cells,
or a functional copy of the GALT cDNA into a patient’s
own genetic material, is intriguing. This approach would
presumably mitigate or solve the metabolic problem, and
not simply block it in some cells. In short, the treatment
might not need to be truly systemic, because even partial
correction, or correction of the defect in some cells but not
others, should provide the body with a route to eliminate
excess galactose from the bloodstream.
Timing of intervention
One of the key challenges to prevention of POI in classic
galactosemia remains the uncertainty of when the funda-
mental damage occurs. Given that folliculogenesis occurs
in utero, it remains possible that most if not all of the
“ovarian damage” has already occurred prior to birth. If
this is the case, strategies for intervention may need to
target the prenatal period, though a host of additional
concerns would accompany such early intervention. Given
that postnatal intervention may also carry potentially
serious risks, it will be important to know that there is a
good chance for success to justify those risks. Alterna-
tively, if the damage is not prenatal, or is reversible, it will
be important to know when in the postnatal period any
given form of intervention will have the greatest chance
for success.
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